The phase 2 AMULET trial evaluated amlenetug, an anti-α-synuclein monoclonal antibody, in MSA patients. While it did not meet its primary endpoint, the antibody showed a non-significant 19% slowing of disease progression with an acceptable safety profile, warranting further phase 3 investigation.